Sanofi gains FDA clearance for Gaucher disease pill
The approval culminates a winding development journey for Infilbray, and provides Sanofi with a new source of income ahead of Dupixent’s looming patent expiration.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.